首页> 外文期刊>Journal of Medicinal Chemistry >New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
【24h】

New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.

机译:新的1-芳基-3-(4-芳基哌嗪-1-基)丙烷衍生物对5-HT1A血清素受体和血清素转运蛋白具有双重作用,是一类新型的抗抑郁药。

获取原文
获取原文并翻译 | 示例
           

摘要

In a search toward new and efficient antidepressants, 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives were designed, synthesized, and evaluated for 5-HT reuptake inhibition and 5-HT1A receptor antagonism. This dual pharmacological profile should lead, in principle, to a rapid and pronounced enhancement in serotoninergic neurotransmission and consequently to a more efficacious treatment of depression. The design was based on coupling structural moieties related to inhibition of serotonin reuptake, such as gamma-phenoxypropylamines, to arylpiperazines, typical 5-HT1A ligands. In binding studies, several compounds showed affinity at the 5-HT transporter and 5-HT1A receptors. Antidepressant-like activity was initially assayed in the forced swimming test with those compounds with Ki < 200 nM in both binding studies. Functional characterization was performed by measuring the intrinsic effect on rectal temperature in mice and also the antagonism to 8-OH-DPAT-induced hypothermia. The most efficacious compounds (12f, 23gE, 28a, and 28b) were further explored for their ability to antagonize 8-OH-DPAT-induced inhibition of forskolin-stimulated cAMP formation in a cell line expressing the 5-HT1A receptor. Furthermore, the antidepressant-like properties of 12f, 28a, and 28b, which exhibited 5-HT1A receptor antagonistic property in the latter study, were also evaluated in the learned helplessness test in rats. Among these three compounds, 28b (1-benzo[b]thiophene-3-yl)-3-[4-(2-methoxyphenyl)-1-ylpropan-1-ol) showed the higher affinity at both the 5-HT transporter and 5-HT1A receptors (Ki = 20 nM in both cases) and was also active in the other pharmacological tests. Such a pharmacological profile could lead to a new class of antidepressants with a dual mechanism of action and a faster onset of action.
机译:为了寻求新的有效的抗抑郁药,设计,合成了1-芳基-3-(4-芳基哌嗪-1-基)丙烷衍生物,并对5-HT再摄取抑制和5-HT1A受体拮抗作用进行了评估。原则上,这种双重药理学特征应导致5-羟色胺能神经传递的快速而明显的增强,从而导致抑郁症的更有效治疗。该设计基于与抑制5-羟色胺再摄取有关的结构部分,例如γ-苯氧基丙胺,与典型的5-HT1A配体芳基哌嗪偶联。在结合研究中,几种化合物对5-HT转运蛋白和5-HT1A受体表现出亲和力。在两个结合研究中,最初在强迫游泳试验中使用Ki <200 nM的那些化合物测定了抗抑郁样活性。通过测量对小鼠直肠温度的内在作用以及对8-OH-DPAT诱导的体温过低的拮抗作用,进行功能表征。进一步研究了最有效的化合物(12f,23gE,28a和28b)在表达5-HT1A受体的细胞系中拮抗8-OH-DPAT诱导的福斯科林刺激的cAMP形成的抑制作用。此外,还在后天研究中表现出5-HT1A受体拮抗作用的12f,28a和28b的抗抑郁样性质,也在大鼠的学习性无助测试中进行了评估。在这三种化合物中,28b(1-苯并[b]噻吩-3-基)-3- [4-(2-甲氧基苯基)-1-基丙-1-醇)对5-HT转运蛋白均具有较高的亲和力和5-HT1A受体(两种情况下,Ki = 20 nM),并且在其他药理试验中也很活跃。这种药理学特征可以导致具有双重作用机制和更快起效的新型抗抑郁药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号